# Previse Dx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/previse-dx

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.previsedx.com
- Total disclosed funding: $3M
- Latest round: Seed (Mar 21, 2023)
- Investors on record: 4

## About

Based in Maryland, US, and founded in 2018, Capsulomics, Inc., dba Previse Dx, is a biotechnology company that specialises in the fields of diagnostics, medical devices, medicine, early detection, and MedTech. Dan Lunz (CEO) and Stephen Meltzer (CMO) are the co-founders of the company. In March 2023, Previse Dx raised USD 3 million in seed funding from the Maryland Technology Development Corporation, including Gaingels, Riptide Venture, and Wexford Science and Technology.

The company specialises in cancer biomarkers, Esopredict™ publications, and pipeline publications. Esopredict™ provides prognostic information to gastroenterologists to assist them in identifying patients with Barrett's oesophagus who are likely to proceed to high grade dysplasia or esophageal cancer. The firm offers Esopredict™ for both patients and providers. Previse's early-detection method combines a standard test with unique DNA biomarkers that diagnose disease precisely.

The organisation plans to use the March 2023 funding to expand commercial operations and build a pipeline for clinical utility research.

## Funding rounds

- Seed, Mar 21, 2023, $3M — Gaingels, Riptide Ventures, Wexford SciTech Venture Fund, TEDCO

## Investors

- Gaingels (https://capitalatlas.ai/funds/gaingels) — Seed
- Riptide Ventures (https://capitalatlas.ai/funds/riptide-ventures) — Seed
- Wexford SciTech Venture Fund (https://capitalatlas.ai/funds/wexford-scitech-venture-fund) — Seed
- TEDCO (https://capitalatlas.ai/funds/tedco) — Seed